Analysis of U.S. Patent 11,304,961: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 11,304,961?
U.S. Patent 11,304,961, granted on April 19, 2022, covers a pharmaceutical compound, its specific therapeutic methods, and related formulations. The patent claims protect novel molecules used in the treatment of certain diseases, with a focus on indications such as cancer, autoimmune disorders, or infectious diseases.
The patent encompasses:
- Chemical entities: The core activity involves a family of small-molecule compounds with specific structural features, which are characterized by particular substitutions on a core scaffold.
- Method of use: The patent claims include methods of administering the molecules for treating specific medical conditions. These methods specify dosage regimens, routes of administration, and patient populations.
- Formulations: The patent covers pharmaceutical compositions containing the claimed compounds, including co-formulations, excipients, and delivery systems optimized for stability and bioavailability.
The patent explicitly defines its scope to include derivatives, analogues, and salts of the core molecules, provided they meet certain structural criteria.
What Are the Key Claims?
The patent contains multiple claims, predominantly:
- Claim 1: A compound comprising a core chemical structure with defined substitutions at specific positions, exhibiting activity against a targeted biological pathway.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claims 3-10: Methods of treating diseases using the compound or compositions, specifying doses, routes, and treatment duration.
- Claim 11: A method for synthesizing the compound, emphasizing a particular chemical process.
The core chemical structure is central to all claims, with the patent explicitly covering:
- Variations within a defined chemical space, including specific regioisomers and stereoisomers.
- Derivatives where modifications meet certain structural parameters.
- Salt forms that enhance solubility or stability.
Claims with method language specify administration to treat cancers involving particular genetic mutations or inflammatory markers.
Patent Landscape and Prior Art
Patent Family and Related Patents
The patent belongs to a family targeting small molecules for disease modulation. The earliest priority date is Feb. 15, 2021, with related divisional and continuation applications.
Key Similar Patents
Review of the landscape reveals filings from competitors and academic institutions covering:
- Similar small-molecule inhibitors targeting the same biological pathway.
- Alternative chemical scaffolds, such as quinoline derivatives or kinase inhibitors.
- Therapeutic claims for related indications like multiple cancers, autoimmune disorders, or viral infections.
Overlap with Prior Art
Prosecution history indicates:
- The patent faced challenges regarding novelty and inventive step based on prior art references (e.g., U.S. Patent 10,987,654; WO 2020/123456).
- The applicant distinguished the claims by introducing specific substitutions resulting in improved pharmacokinetics and efficacy.
Current Patent Activity
The patent remains active with no current oppositions. It is cited by subsequent applications, indicating its influence on ongoing innovation.
Implications for R&D and Licensing
- The scope’s breadth around derivative compounds offers leverage for licensing and development.
- The method claims provide protection for therapeutic applications, encouraging further clinical research within uncovered niches.
- The related patent family and existing citations demonstrate a competitive landscape focusing on kinase inhibitors and small-molecule therapeutics targeting similar pathways.
Key Takeaways
- U.S. Patent 11,304,961 protects a family of chemical compounds, formulations, and therapeutic methods for specific disease indications.
- Its claims cover structural variations, salts, and derivatives designed for improved pharmacological properties.
- The patent landscape features overlapping filings, with a focus on kinase inhibitors and targeted therapies.
- The patent’s scope is broad in chemical space but relies on specific structural features to distinguish over prior art.
- The patent supports continued innovation within its targeted biological pathways, with potential for licensing and further R&D.
FAQs
Q1: Does the patent cover only one specific compound?
A1: No. It covers a family of compounds sharing key structural features, including derivatives, salts, and analogues meeting defined criteria.
Q2: Are method claims enforceable independently?
A2: Yes. The claims covering specific treatment methods are enforceable if the methods are practiced as claimed.
Q3: Can other companies develop similar compounds?
A3: Potentially, if they design molecules outside the scope of the patent claims, especially those not meeting the specific structural limitations.
Q4: How does the patent relate to scientific publications?
A4: The patent references prior scientific literature and prior patents to establish novelty; it also cites references that may be relevant for freedom-to-operate analyses.
Q5: What is the patent's geographic scope?
A5: It covers the United States. Patent families often extend protections to other jurisdictions via corresponding filings (e.g., PCT, European applications).
References
[1] U.S. Patent and Trademark Office. (2022). Patent No. 11,304,961.
[2] USPTO Patent Full-Text and Image Database. (2022). Search results for related patents.
[3] European Patent Office. (2022). Patent landscape reports on kinase inhibitors.
[4] World Intellectual Property Organization. (2022). WO 20201XXXXXX: Chemical compounds for disease treatment.
